FDA Brief

Warning letters Drugs

FDA warning letter to

Intimate Rose

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.

What happened

FDA reviewed Intimate Rose's website in August 2025 and found it offered compounded semaglutide and tirzepatide drug products. The site claimed these products had the "same active ingredient as Ozempic and Wegovy" and "same active ingredient as Mounjaro and Zepbound." FDA said those claims are false or misleading because compounded drugs are not FDA-approved.

What FDA found

  1. The website claimed compounded semaglutide had the same active ingredient as Ozempic and Wegovy, which FDA says falsely implies it is the same as FDA-approved drugs.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The website claimed compounded tirzepatide had the same active ingredient as Mounjaro and Zepbound, which FDA says falsely implies it is the same as FDA-approved drugs.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. FDA says the misleading claims make the compounded drugs misbranded, meaning falsely promoted, and shipping them across state lines is prohibited.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. The letter also says receiving misbranded drugs in interstate commerce is illegal.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells Intimate Rose to immediately stop using the misleading claims and to respond in writing within 15 working days describing the specific steps taken to fix the violations and prevent recurrence, with supporting documents.

Who should pay attention

  • online telehealth sellers of compounded GLP-1 drugs
  • compounding pharmacies that advertise semaglutide or tirzepatide
  • compliance teams reviewing drug marketing claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk